Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03761056
Title Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kite, A Gilead Company
Indications

B-cell lymphoma

Therapies

axicabtagene ciloleucel + Cyclophosphamide + Fludarabine

Age Groups: adult | senior
Covered Countries USA | FRA | CAN


No variant requirements are available.